A clinical-stage Oncology company Prescient Therapeutics Limited (ASX:PTX) revealed that its phase 1b study of PTX-100 for cancer will move to the next dose level of 1,000 mg/m2 after half that amount was demonstrated safe in the first cohort of patients.
The Study now expands to Australia, to include PASO in South-Eastern Victoria under the guidance of Professor Vinod Ganju.
PTX-100 is being tested against several tumors, as it is not targeting tumour origin but two specific genetic mutations (Ras and RhoA).
The share price of PTX climbed by 11.429% to $0.039 at AEST 12:02 PM.